Xcovery Holdings, Inc.
About
Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases. On December 18, 2024, the Food and Drug Administration approved ensartinib (Ensacove, Xcovery Holdings, Inc.) for adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK-inhibitor. Full prescribing information for Ensacove will be posted on Drugs@FDA.
US
168 SE 1st Street, Suite 1100, Miami, Florida
33131
Privately Held
21
Pharmaceutical Manufacturing
Oncology; ALK positive lung cancer; lung cancer; clinical trials ; ALK+ NSCLC; kinase inhibitors; oncology research; bio-pharmaceutics; pharmaceutics; cancer; ALK inhibitor; ensartinib ; cancer research; pharma ; bio-pharma; clinical studies; research ; investigational agents ; cancer therapy ; hematology; clinical research ; cancer research
Top Decision Makers · 2
Executive Vice President
Fuqiang Liu
United States
******@***.com
Phone
(**) *** ****
Clinical Trial Document Manager
Stephanie Dietz
United States
******@***.com
Phone
(**) *** ****
Find the Right Leads
Find Verified Contact Data
What LeadContact does well
Find verified emails, phone numbers, and decision-makers with 98% accuracy.
Find Leads
Find the right people by company, role, industry, location, and more.
925M+ professional profiles
Find Emails
Access verified email addresses for your target contacts.
657M+ emails
Find Phone Numbers
Get cross-validated phone data from multiple top sources.
239M+ phone numbers
More Accurate. Lower Cost.
Find contact data in 1 tool with 98% accuracy
LeadContact integrates leading enrichment tools to deliver more accurate contact data—without paying for each one.
Great conversations start with the right contact.
It’s time to find yours.